OBI-858 Long-Acting Botulinum Toxin Nears Taiwan Phase III Readout as Global Licensing Efforts Accelerate
OBIGEN Pharma (Ticker: 7876.TWO) today announced that it will participate in BIO Asia–Taiwan 2026, taking place from July 16–19, 2026, and has once again been invited to present at the Investment Summit Roadshow on July 15. During the summit, the Company will deliver a presentation titled "Global Commercialization Strategy and Competitive Advantages of Long-Acting Botulinum Toxin OBI-858," highlighting the latest clinical progress of OBI-858 with international investors, multinational pharmaceutical companies, and industry partners.
Results from the Taiwan Phase II clinical study of OBI-858 demonstrated a favorable safety profile, rapid onset of action, prolonged efficacy, and low immunogenicity. The Taiwan Phase III clinical program has successfully completed enrollment of approximately 600 subjects and is entering the final stages of study execution during the third quarter of 2026. The Company is targeting database lock and topline results by the end of 2026, positioning OBI-858 for subsequent Biologics License Application (BLA) submission.
"2026 marks a pivotal year in OBIGEN's journey toward global commercialization," said Patricia Chou, Chief Executive Officer of OBIGEN Pharma. "The U.S. FDA has agreed to accept clinical data generated in Taiwan to support the development program. We are currently advancing our U.S. Phase II clinical trial while preparing for a seamless transition into Phase III, accelerating OBI-858 entry into the global market."
Ms. Chou added that OBIGEN is actively expanding its international business development efforts and is currently engaged in licensing and distribution discussions with more than ten global pharmaceutical and medical aesthetics companies. As the Taiwan Phase III readout approaches, the Company expects to further accelerate strategic partnerships and worldwide commercialization initiatives.
Event Information